AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jimenez, E.
Right arrow Articles by Gargallo-Viola, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jimenez, E.
Right arrow Articles by Gargallo-Viola, D.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, August 2002, p. 2648-2650, Vol. 46, No. 8
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.8.2648-2650.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Therapeutic Efficacies of GW471552 and GW471558, Two New Azasordarin Derivatives, against Pneumocystosis in Two Immunosuppressed-Rat Models

Elena Jimenez,1 Antonio Martínez,1 El Moukhtar Aliouat,2 Jesus Caballero,3 Eduardo Dei-Cas,4 and Domingo Gargallo-Viola1*

GlaxoSmithKline, Madrid,1 Laboratorios Hipra, Girona, Spain,3 Laboratory of Parasitology, School of Pharmacy, Lille-II University,2 Lille-CHRU, Ecology of Parasitism, Institute Pasteur of Lille, Lille, France4

Received 31 January 2002/ Returned for modification 11 March 2002/ Accepted 14 May 2002


   ABSTRACT
Top
 Abstract
Text
 References
 
Two new azasordarins, GW471552 and GW471558, were studied in vivo for treatment of Pneumocystis carinii pneumonia. In the Wistar rat spontaneous pneumonia model, both azasordarins significantly reduced the number of P. carinii cysts per gram of lung homogenate when administered at 1 mg/kg of body weight twice a day for 10 days. In a nude rat inoculation model, both compounds showed therapeutic efficacy at 0.25 mg/kg twice a day for 10 days.


   TEXT
Top
 Abstract
 Text
References
 
Pneumocystis carinii, remains an important pathogen for the broad spectrum of immunocompromised individuals, despite significant advances in antimicrobial therapy (15). Deep impairments in cell immunity, probably associated with pulmonary surfactant changes, are critical conditions for proliferation (8). This agent is an important cause of community-acquired pneumonia in individuals with a wide variety of underlying immune deficiencies and remains the most common life-threatening opportunistic infection diagnosed in human immunodeficiency virus patients, despite the dramatic decline in incidence due to widespread use of highly active antiretroviral therapy (19). In most non-AIDS immunocompromised patients, such as organ transplant recipients, the risk of disease is in the range of 5 to 15% (depending on the nature and duration of the immunosuppression). Among patients who are not receiving prophylactic therapy, P. carinii causes pneumonia in 10% of heart, liver, and kidney transplant recipients in the first 6 months posttransplantation (11). In addition, the incidence of this infection appears to be higher in children than in adults (6).

The inability of many patients to tolerate prophylaxis or treatment with traditional therapeutic standards, such as trimethoprim-sulfamethoxazole, atovaquone, or pentamidine (19), originated a search for new agents for prevention and treatment of Pneumocystis infection in immunocompromised hosts.

Sordarins are a new class of antifungal agents that act by inhibiting the protein synthesis elongation cycle (5, 10). Sordarin derivatives have demonstrated a potent and relatively broad-spectrum antifungal activity in in vitro (14) and in vivo studies (4, 20, 22). A further evolution of this class of compounds has led to a new family of substances, azasordarins, that have a similar biological profile but easier chemical synthesis. Azasordarins have demonstrated excellent in vitro activity against key fungal pathogens, including P. carinii (13), and therapeutic efficacy in experimental rodents of oral and vulvovaginal candidiasis (21).

In order to determine the potential in vivo profile of azasordarins, two compounds have been selected for the treatment of P. carinii pneumonia (PCP) as representatives of this new family of antifungal agents and have been evaluated in two experimental infection models of pneumonia in immunosuppressed rats.

(This work was presented in part at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 17 to 20 September 2000 [A. Martínez, E. Jiménez, E. M. Aliouat, J. Caballero, E. Dei-Cas, and D. Gargallo-Viola, Abstr. 40th Intersci. Conf. Antimicrob. Agents Chemother., abstr. 1096].)

Antifungal agents. GW471552 and GW471558 were synthesized at GlaxoSmithKline (Tres Cantos, Madrid, Spain). The compounds, as potassium salts, were initially dissolved in sterile distilled water at a starting concentration of 2 mg/ml and diluted in sterile distilled water to reach the desired concentrations. Solutions were prepared just before use and protected from light. Wellcome Laboratory graciously provided trimethoprim-sulfamethoxazole as Septrim.

Experimental PCP. The therapeutic efficacy of GW471552 and GW471558 was evaluated with two experimental models in immunosuppressed rats: (i) Wistar rats, which develop spontaneous infection after immunosuppressive treatment; and (ii) nude rats intratracheally infected with P. carinii organisms. Seven-week-old female Wistar rats (Iffa Credo, Lyon, France) and 10-week-old female Fischer-344 RNU/rnu rats from a Pneumocystis-free colony (Lille Pasteur Institute) were used in this study.

The research complied with national legislation and with company policy on the care and use of animals according to the related code of practice.

(i) Wistar rat model. Pneumonia developed spontaneously after 9 weeks of immunosuppressive treatment with dexamethasone at 2 mg/liter in drinking water (Fortecortin; Merck Laboratories, Madrid, Spain). Tetracycline (Terramicine; Pfizer Laboratories, Madrid, Spain) at 1 g/liter was added to the drinking water as an antibacterial prophylactic agent throughout the study. The drug treatment was started after 9 weeks of immunosuppression.

(ii) Nude rat model. The animals were given dexamethasone (2) in the drinking water (1 mg/liter) throughout the study. After 2 weeks of dexamethasone treatment, rats were anesthetized and infected by nonsurgical intratracheal inoculation with 9 x 107 Pneumocystis organisms per rat (E. M. Aliouat, S. Ferrar, J. C. Cailliez, A. E. Wakefield, J. Sparrowe, C. Recourt, D. Camus, and E. Dei-Cas, submitted for publication).

Antifungal treatment. Antifungal therapy was started 5 or 9 weeks after corticosteroid treatment in the nude or Wistar rat model, respectively. Groups of five rats each were treated subcutaneously with GW471552 or GW471558 twice a day for 10 consecutive days. Doses of 1 and 5 mg/kg of body weight were administered to Wistar rats. Nude rats were treated with doses of 0.25 and 0.5 mg/kg of body weight. Septrim, used as reference compound in both models, was administered at 50 (trimethoprim)/250 (sulfamethoxazole) mg/kg of body weight orally (by gavage) once a day for 10 consecutive days.

Assessment of therapeutic efficacy. Therapeutic efficacy was assessed by counting P. carinii cysts in lung homogenates and comparing them with those of the untreated controls at the end of the experiment. Twenty-four hours after the end of the treatment, animals were sacrificed, and the lungs were aseptically removed and processed for parasite quantitation with toluidine blue O stain (Sigma Aldrich, Alcobendas, Madrid, Spain) as previously described (1, 24).

The total numbers of P. carinii cysts (Tc) were calculated according the equation Tc = (n x Sa x R)/Fa, where n is the average number of microorganisms per oil immersion field (20 fields counted for each smear), Sa is the 2-µl smear area, R is the ratio of the total volume of the microorganisms in suspension to the calibrate smear volume (2 µl), and Fa is the oil immersion field area (2). The limit of detection of this procedure was 103 cysts per g of lung.

One day before starting antifungal treatment, three animals were sacrificed, and lungs were processed to verify the level of infection and quantify the number of P. carinii cysts per gram of lung. The results indicate that all animals studied developed P. carinii pneumonia.

Statistical analysis. The Kruskal-Wallis nonparametric test was used to statistically compare the number of cysts of P. carinii recovered from the lungs of the experimental groups. Multiple comparisons of treated groups versus the control group were performed by Dunn's method. All statistical evaluations were performed with the SigmaStat statistical package (Jandel Scientific, Erkrath, Germany). P values of <=0.05 were considered statistically significant.

Two experimental models of pneumocystosis were used to evaluate the therapeutic efficacy of GW471552 and GW471558.

Therapeutic efficacy in Wistar rats. Before starting antifungal treatment, animals developed PCP with 7.0 ± 0.3 (n = 3) log cysts/g of lung. The number of organisms quantified 24 h after the end of the treatment from untreated animals was 6.9 ± 0.4 log cysts/g of lung. The experimental results obtained from rats with PCP, either untreated or treated with GW471552 or GW471558, are summarized in Table 1. After the antifungal chemotherapy, rats treated with 1.0 mg of GW471552 or GW471558 per kg showed a statistically significant reduction in the number of cysts recovered from lungs, with 5.0 ± 0.6 log cysts/g of lung in both cases, which represents reductions of 98.21 and 97.90% (P < 0.05), respectively. GW471552 and GW471558 administered at 5 mg/kg also reduced the log number of cysts per gram of lung: 98.88 and 98.96% (P < 0.05), respectively. Septrim significantly reduced (P < 0.05) the number of cysts per gram of lung compared to the level in controls (98.96%).


View this table:
[in this window]
[in a new window]
  		TABLE 1. Therapeutic efficacies of GW471552 and GW471558 against experimental pneumonia in Wistar ratsa

 
Therapeutic efficacy in nude rats. Before the start of antifungal treatment, the P. carinii burden in infected rats was 7.1 ± 0.2 log cysts/g of lung (n = 3). Saline-treated control animals showed 7.3 ± 0.2 log cysts per g of lung at the end of the treatment. The therapeutic effects of treatment with GW471552 and GW471558 on the P. carinii pulmonary burden in infected rats are summarized in Table 2. GW471558 was able to reduce the lung burden to below the limit of detection in all of the animals treated at 0.5 mg/kg. At this dose, GW471552 exhibited a 99.99% reduction compared with untreated controls. In addition, the two azasordarins were effective when administered at 0.25 mg/kg. Septrim reduced the number of cysts per gram of lung compared to controls, showing a reduction of 80.04%.


View this table:
[in this window]
[in a new window]
  		TABLE 2. Therapeutic efficacies of GW471552 and GW471558 against experimental pneumonia in nude ratsa

 
P. carinii remains an important pathogen in AIDS patients and other immunocompromised individuals (16). Pneumonia caused by P. carinii is usually treated with trimethoprim-sulfamethoxazole, atovaquone, or pentamidine, which are also used in primary and secondary prevention (12, 19). The relatively high frequency of adverse reactions (18) and appearance of resistance (17) to these drugs reflect the need for new therapeutic approaches.

Sordarins are a new kind of antifungal agents different from other antifungal compounds because of their novel mechanism of action. They are highly selective fungal protein synthesis inhibitors that interact with the translation elongation factor EF-2 and the large ribosomal subunit stalk, rpP0, thus inhibiting translation and elongation in fungal cells (5, 10). Azasordarins have demonstrated excellent in vitro and in vivo activity against key fungal pathogens. The efficacy of azasordarins against P. carinii has been demonstrated in vitro: 50% inhibitory concentration values of GW471552 and GW471558 against P. carinii used for experimental infections were 0.001 and <=0.001 µg/ml, respectively. However, confirmation of therapeutic efficacy in rodent models is still necessary as a basis for clinical trials.

The aim of this study was to evaluate the therapeutic efficacy of two new azasordarins against experimental PCP. We have shown that azasordarins are highly potent, reducing the number of cysts from lungs with a good correlation between dose and response in the two immunosuppressed rat models evaluated. Azasordarins showed better therapeutic efficacies than those exhibited under our experimental conditions by antipneumocystis drugs, such as Septrim, and this fact represents a clear advantage over the other three main groups of systemic antifungals currently in clinical use: polyenes, azoles, and allylamines.

In addition, the low toxicity of GW471552 and GW471558 has been demonstrated in vitro (13) and confirmed by preliminary mouse toxicity tests [E. Herreros, A. Martínez, M. J. Almela, E. Jiménez, S. Lozano, M. J. Pérez, and D. Gargallo-Viola, Abstr. 40th Intersci. Conf. Antimicrob. Agents Chemother., abstr. 1691, 2000].

In conclusion, the results of the present study are encouraging, although further investigations to confirm the potential of azasordarins for effective antifungal treatment of PCP in humans are needed.


   ACKNOWLEDGMENTS
 
We thank members of the Pharmacological Research Centre for excellent technical assistance, Esperanza Herreros for providing all in vitro data, and members of the Organic Chemistry Group for compound synthesis.

E. Jiménez and A. Martínez contributed equally to the work presented in this publication.


   FOOTNOTES
 
* Corresponding author. Mailing address: GlaxoSmithKline, Parque Tecnológico de Madrid, Severo Ochoa, 2, 28760 Tres Cantos, Madrid, Spain. Phone: 34.91.80.70.481. Fax: 34.91.80.70.595. E-mail: dgv28867{at}gsk.com. Back


   REFERENCES
Top
 Abstract
 Text
 References
 

  1. Aliouat, E. M., E. Dei-Cas, M. A. Ouassi, F. Palluault, B. Soulez, and D. Camus. 1993. In vitro attachment of Pneumocystis carinii from mouse and rat origin. Biol. Cell 77:209-217.[CrossRef][Medline]
  2. Aliouat, E. M., A. Martínez, E. Jiménez, E. Dei-Cas, C. Mullet, P. Delcourt, and D. Gargallo-Viola. 1997. Development of pneumocystosis animal models: corticosteroid-treated Wistar rat; SCID mouse and nude rat. J. Eukaryot. Microbiol. 44:41S-42S.[Medline]
  3. Atzori, C., E. M. Aliouat, M. S. Bartlett, L. Dujardin, A. Cargnel, and E. Dei-Cas. 2001. Current in vitro culture systems for Pneumocystis. FEMS Immunol. Med. Microbiol. 22:169-172.
  4. Aviles, P., C. Falcoz, R. San Roman, and D. Gargallo-Viola. 2000. Pharmacokinetics-pharmacodynamics of a sordarin derivative (GM 237354) in a murine model of lethal candidiasis. Antimicrob. Agents Chemother. 44:2333-2340.[Abstract/Free Full Text]
  5. Capa, L., A. Mendoza, J. L. Lavandera, F. Gómez de las Heras, and J. F. García-Bustos. 1998. Translation elongation factor 2 is a part of the target for a new family of antifungals. Antimicrob. Agents Chemother. 42:2694-2699.[Abstract/Free Full Text]
  6. Colombo, J. L., P. H. Samut, A. N. Langnas, and B. W. Shaw. 1992. The spectrum Pneumocystis carinii infection after liver transplantation in children. Transplantation 54:621-624.[Medline]
  7. Dei-Cas, E., M. Brun-Pascaud, V. Bille-Hansen, A. Allaert, and E. M. Aliouat. 1988. Animal models of pneumocystosis. FEMS Immunol. Med. Microbiol. 22:163-168.
  8. Dei-Cas, E., and J. Cailliez. 1998. Pneumocystis and pneumocystosis: advances in Pneumocystis research. FEMS Immunol. Med. Microbiol. 22:1-4.[CrossRef][Medline]
  9. Dei-Cas, E., J. C. Cailliez, and Members of European Concerted Action on Pneumocystis carinii. 1996. In vitro systems in pneumocystis research. Parasitol. Today 12:245-249.
  10. Domínguez, J. M., V. A. Kelly, O. S. Kinsman, M. S. Marriott, F. Gómez de las Heras, and J. J. Martín. 1998. Sordarins: a new class of antifungals with selective inhibition of the protein synthesis elongation cycle in yeasts. Antimicrob. Agents Chemother. 42:2274-2278.[Abstract/Free Full Text]
  11. Dummer, J. S. 1990. Pneumocystis carinii infections in transplant recipients. Semin. Respir. Med. 5:50-57.
  12. Fishman, J. A. 1998. Prevention of infection due to Pneumocystis carinii. Antimicrob. Agents Chemother. 42:995-1004.[Free Full Text]
  13. Herreros, E., M. J. Almela, S. Lozano, F. Gómez de las Heras, and D. Gargallo-Viola. 2001. Antifungal activities and cytotoxicity of six new azasordarins. Antimicrob. Agents Chemother. 45:3132-3139.[Abstract/Free Full Text]
  14. Herreros, E., C. M. Martínez, M. J. Almela, M. S. Marriott, F. Gómez de las Heras, and D. Gargallo-Viola. 1998. Sordarins: in vitro activities of new antifungal derivatives against pathogenic yeasts, Pneumocystis carinii, and filamentous fungi. Antimicrob. Agents Chemother. 42:2863-2869.[Abstract/Free Full Text]
  15. Hughes, W. T. 1987. Pneumocystis and pneumocystosis, 2nd ed. CRC Press, Boca Raton, Fla.
  16. Hughes, W. T. 1991. Pneumocystis carinii pneumonia: new approaches to diagnosis, treatment and prevention. Pediatr. Infect. Dis. J. 10:391-399.[Medline]
  17. Hughes, W. T., S. W. LaFon, J. D. Scott, and H. Masur. 1995. Adverse events associated with trimethoprim-sulfamethoxazole and atovaquone during the treatment of AIDS-related Pneumocystis carinii pneumonia. J. Infect. Dis. 171:1295-1301.[Medline]
  18. Huovinen, P. 2001. Resistance to trimethoprim-sulfamethoxazole. Clin. Infect. Dis. 32:1608-1614.[CrossRef][Medline]
  19. Kovacs, J. A., V. J. Gill, S. Meshnick, and H. Masur. 2001. New insights into transmission, diagnosis, and drug treatment of Pneumocystis carinii pneumonia. JAMA 286:2450-2460.[Abstract/Free Full Text]
  20. Martínez, A., P. Avilés, E. Jiménez, J. Caballero, and D. Gargallo-Viola. 2000. Activities of sordarins in experimental models of candidiasis, aspergillosis, and pneumocystosis. Antimicrob. Agents Chemother. 44:3389-3394.[Abstract/Free Full Text]
  21. Martínez, A., S. Ferrer, I. Santos, E. Jiménez, J. Sparrowe, J. Regadera, F. Gómez de las Heras, and D. Gargallo-Viola. 2001. Antifungal activities of two new azasordarins, GW471552 and GW471558, in experimental model of oral and vulvovaginal candidiasis in immunosuppressed rats. Antimicrob. Agents Chemother. 45:3304-3309.[Abstract/Free Full Text]
  22. Martínez, A., J. Regadera, E. Jiménez, I. Santos, and D. Gargallo-Viola. 2001. Antifungal efficacy of GM237354, a sordarin derivative, in experimental oral candidiasis in immunosuppressed rats. Antimicrob. Agents Chemother. 45:1008-1013.[Abstract/Free Full Text]
  23. Merali, S., U. Frevert, J. H. Williams, K. Chin, R. Bryan, and A. B. Clarckson, Jr. 1999. Continuous axenic cultivation of Pneumocystis carinii. Proc. Natl. Acad. Sci. USA 96:2402-2407.[Abstract/Free Full Text]
  24. Soulez, B., E. Dei-Cas, F. Palluault, and D. Camus. 1991. Morphological evaluation of Pneumocystis carinii after extraction from infected lung. J. Parasitol. 77:449-453.[CrossRef][Medline]

Antimicrobial Agents and Chemotherapy, August 2002, p. 2648-2650, Vol. 46, No. 8
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.8.2648-2650.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jimenez, E.
Right arrow Articles by Gargallo-Viola, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jimenez, E.
Right arrow Articles by Gargallo-Viola, D.

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS